Enrollment of racial/ethnic minorities in NIAID-funded networks of HIV vaccine trials in the United States, 1988 to 2002

Public Health Reports

Volumn 120, Issue 5, 2005, Pages 543-548

  Djomand, Gaston ^a   Katzman, Joanna ^b   DiTommaso, Dante ^c   Hudgens, Michael G ^d   Counts, George W ^a   Koblin, Beryl A ^e   Sullivan, Patrick S ^f  

^a Fred Hutchinson Cancer Research Center   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d IL   (United States)

^e NEW YORK BLOOD CENTER   (United States)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DATA BASE; DEMOGRAPHY; ETHNIC AND RACIAL GROUPS; ETHNOLOGY; FEMALE; HEALTH CARE ACCESS; HEALTH CARE ORGANIZATION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNITED STATES; VACCINATION;

EID: 25144450496     PISSN: 00333549     EISSN: 00333549     Source Type: Journal    
DOI: 10.1177/003335490512000509     Document Type: Article

References (26)

1. Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S, et al. The need for a global HIV vaccine enterprise. Science 2003 Jun 27;300:2036-9.
2. An HIV vaccine: how long must we wait? [Editorial] Lancet 1998;352(9137):1323.
3. NIAID's HIV Vaccine Trials Network (HVTN) [cited 2004 Dec 22]. National Institute of Allergy and Infectious Diseases. Available from: URL: http://www.niaid.nih.gov/factsheets/hvtn.htm
4. Centers for Disease Control and Prevention. HIV/AIDS surveillance report, 2003 (Vol. 15). Atlanta: Department of Health and Human Services (US), CDC; 2004.
5. Protection of human subjects; Belmont Report: notice of report for public comment. Fed Regist 1979;44(76):23191-7.
6. NIH guidelines on the inclusion of women and minorities as subjects in clinical research [cited 2004 Dec 22]. Available from: URL: http://grants.nih. gov/grants/guide/notice-files/NOT-OD-00-048.html
7. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, et al. Placebo-controlled trial of a recombinant glycoprotein 120 vaccine to prevent HIV infection. J Infect Dis 2005;191:647-9.
8. SAS OnlineDoc. Version 8. Cary (NC): SAS Institute Inc; 1999.
9. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986;73:13-22.
10. Rotnitzky A, Jewell NP. Hypothesis testing of regression parameters in semiparametric generalized linear models for cluster correlated data. Biometrika 1990;77:485-97.
11. Pan W. Akaike's information criterion in generalized estimating equations. Biometrics 2001;57:120-5.
12. Baird KL. The new NIH and FDA medical research policies: targeting gender, promoting justice. J Health Polit Policy Law 1999;24:531-65.
13. Giuliano AR, Mokuau N, Hughes C, Tortolero-Luna G, Risendal B, Ho RCS, et al. Participation of minorities in cancer research: the influence of structural, cultural, and linguistic factors. Ann Epidemiol 2000;10(8 Suppl):S22-34.
14. Corbie-Smith G, Thomas SB, Williams MV, Moody-Ayers S. Attitudes and beliefs of African Americans toward participation in medical research. J Gen Intern Med 1999;14:537-46.
15. Mills E, Cooper C, Guyatt G, Gilchrist A, Rachlis B, Sulway C, Wilson K. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS 2004;18:2235-42.
16. Shavers VL, Lynch CF, Burmeister LF. Knowledge of the Tuskegee study and its impact on the willingness to participate in medical research studies. J Natl Med Assoc 2000;92:563-72.
17. Sengupta S, Strauss RP, DeVellis R, Quinn SC, DeVellis B, Ware WB. Factors affecting African-American participation in AIDS research. J Acquir Immune Defic Syndr 2000;24:275-84.
18. Corbie-Smith G, Thomas SB, St George DM. Distrust, race, and research. Arch Intern Med 2002;162:2458-63.
19. Koblin BA, Avrett S, Taylor PE, Stevens CE. Willingness to participate in HW-1 vaccine efficacy trials and the effect of media events among gay and bisexual men in New York City: Project ACHIEVE. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:165-71.
20. Sheon AR, Wagner L, McElrath MJ, Keefer MC, Zimmerman E, Israel H, et al. Preventing discrimination against volunteers in prophylactic HIV vaccine trials: lessons from a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 1998;19:519-26.
21. Strauss RP, Sengupta S, Kegeles S, McLellan E, Metzger D, Eyre S, et al. Willingness to volunteer in future preventive HIV vaccine trials: issues and perspectives from three U.S. communities. J Acquir Immune Defic Syndr 2001;26:63-71.
22. Novitsky V, Flores-Villanueva PO, Chigwedere P, Gaolekwe S, Bussman H, Sebetso G, et al. Identification of most frequent HLA class I antigen specificities in Botswana: relevance for HIV vaccine design. Hum Immunol 2001;62:146-56.
23. Gilbert P, Popovic V, Gurwith M, Heyward W, Francis D, Sinangil F, et al. Immunologic responses to rgp-120 vaccine and correlation with the risk of HIV infection: results from the world's first HIV vaccine efficacy trial. AIDS Vaccine 2003. 2003 Sep 21; New York.
24. Montefiori D, Metch B, McElrath MJ, Self S, Weinhold K, Corey L. Conditional influence of race and gender on the neutralizing antibody response to candidate HIV-1 vaccines. AIDS Vaccine 2003. 2003 Sep 20; New York.
25. HIV incidence among young men who have sex with menseven U.S. cities, 1994-2000. MMWR Morb Mortal Wkly Rep 2001;50(21):440-4.
26. Bartholow BN, Buchbinder S, Goli V, Celum C, Koblin B, Marmor M, et al. HIV risk behavior change over 24 months of follow-up in a phase-III HIV vaccine efficacy trial. XIV International AIDS Conference. 2002 Sep 7-10; Barcelona, Spain.